Payment overview · 2025
General Payments
$206.65
12 reported records · 8 companies
Healthcare provider profile · identity verified
Jeffrey M Beal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OCEAN GROVE, NJ · NPI 1801891437
Verified facts
What the public records show
CMS Open Payments records show Jeffrey M Beal, M.D. received $206.65 in general payments during 2025 across 12 reported records.
Exact Sciences Corporation accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.59 | 29.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.00 | 22.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.63 | 8.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.33 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.52 | 8.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $16.33 | 7.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.07 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.18 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.65 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.59 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 482 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 54 |
| Losartan Potassium | Losartan Potassium | 284 | 51 |
| Metformin Hcl | Metformin Hcl | 277 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 196 | 17 |
| Gabapentin | Gabapentin | 194 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 38 |
| Tramadol Hcl | Tramadol Hcl | 180 | 28 |
| Omeprazole | Omeprazole | 176 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 34 |
| Lisinopril | Lisinopril | 143 | 27 |
| Montelukast Sodium | Montelukast Sodium | 140 | 26 |
| Carvedilol | Carvedilol | 138 | 28 |
| Trazodone Hcl | Trazodone Hcl | 137 | 17 |
| Amoxicillin | Amoxicillin | 136 | 79 |
| Furosemide | Furosemide | 134 | 22 |
| Eliquis | Apixaban | 125 | 18 |
| Azithromycin | Azithromycin | 122 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 19 |
| Baclofen | Baclofen | 92 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | suppressed |
| Simvastatin | Simvastatin | 87 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 17 |
| Atenolol | Atenolol | 84 | 24 |
| Potassium Chloride | Potassium Chloride | 83 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 12 |
| Sertraline Hcl | Sertraline Hcl | 76 | 16 |
| Clonazepam | Clonazepam | 75 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | suppressed |
| Sucralfate | Sucralfate | 74 | suppressed |
| Xarelto | Rivaroxaban | 74 | suppressed |
| Glimepiride | Glimepiride | 73 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 16 |
| Valsartan | Valsartan | 63 | 13 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Pregabalin | Pregabalin | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Finasteride | Finasteride | 54 | 11 |
| Prednisone | Prednisone | 54 | 20 |
| Allopurinol | Allopurinol | 53 | 13 |
| Ozempic | Semaglutide | 52 | suppressed |
| Repaglinide | Repaglinide | 52 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 14 |
| Cefuroxime | Cefuroxime Axetil | 50 | 14 |
| Famotidine | Famotidine | 50 | 13 |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 23 |
| Meclizine Hcl | Meclizine Hcl | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 11 |
| Temazepam | Temazepam | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Cephalexin | Cephalexin | 30 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 19 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Paricalcitol | Paricalcitol | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.65 · 12 records | Exact Sciences Corporation | AIRSUPRA, Cologuard Collection Kit, JARDIANCE, Kerendia, MOUNJARO, Ozempic, REXULTI, Rybelsus, VIVITROL | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error